Overview
A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function
Status:
Unknown status
Unknown status
Trial end date:
2014-06-01
2014-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Microvascular dysfunction is a key determinant of pathogenesis and outcome in patients suffering an acute myocardial infarction. The investigators hypothesise that treatment with intracoronary abciximab, a potent anti platelet agent, at the time of coronary stent insertion, will improve microvascular function.Phase:
N/AAccepts Healthy Volunteers?
NoDetails
Lead Sponsor:
University of MelbourneTreatments:
Abciximab
Criteria
Inclusion Criteria:- Patient with acute coronary syndromes
Exclusion Criteria:
- Patient with untreated malignancy, disseminated malignancy, active inflammatory
diseases, active infectious diseases patients unable to give informed consent Patients
with STEMI